Zerbaxa, a combination of cephalosporin ceftolozane and tazobactam, was initially approved in 2014 to treat intra-abdominal infections and complicated urinary tract infections.
The new indication for the drug, given by injection, was demonstrated in a double-blind study that compared the drug to another antibacterial drug. Mortality and cure rates for Zerbaxa were similar to the treatment used as a comparison.
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are life-threatening pulmonary infections that often affect already vulnerable patients. They are also the second most common type of hospital-acquired infection in the U.S.
Zerbaxa is manufactured by Merck.
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
Mallinckrodt to spin off generics unit
Pharma exec Martin Shkreli sues Retrophin directors from prison
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
